Dr. Pandalai on the Efficacy of Cytoreductive Surgery Plus HIPEC in Colorectal Peritoneal Carcinomatosis
In Partnership With:
Prakash Pandalai, MD, discusses the efficacy of aggressive cytoreductive surgery plus heated intraperitoneal chemotherapy in colorectal peritoneal carcinomatosis.
Prakash Pandalai, MD, assistant professor of surgery, surgical oncologist, University of Kentucky, Markey Cancer Center, discusses the efficacy of aggressive cytoreductive surgery plus heated intraperitoneal chemotherapy (HIPEC) in colorectal peritoneal carcinomatosis.
Historically, patients with colorectal peritoneal carcinomatosis who are treated with chemotherapy alone typically have a median overall survival of less than 1 year, Pandalai says. Adding aggressive cytoreductive surgery and HIPEC to traditional chemotherapy can improve outcomes for these patients.
Single- and multi-institutional series have demonstrated an improved median OS with this regimen in the range of 40to 45 months, which is quite profound for these patients, Pandalai concludes.
